+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Generic Injectables Market - Global Forecast 2026-2032- Product Image
Generic Injectables Market - Global Forecast 2026-2032- Product Image
Sale

Generic Injectables Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 5887534
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Generic Injectables Market is projected to reach USD 44.05 Billion in 2026. It is expected to continue growing at a CAGR of 11.14%, reaching USD 84.10 Billion by 2032.

Generic injectables are off-patent parenteral medicines administered through routes such as intravenous, intramuscular, and subcutaneous delivery. They are clinically important in hospitals, emergency care, oncology, anti-infective treatment, anesthesia, and chronic disease management. Their strategic value is closely linked to affordability, continuity of supply, manufacturing quality, and the ability to meet stringent sterile-production requirements.

Sterile Manufacturing and Supply Resilience Are Reshaping Competition

The landscape is being transformed by tighter expectations for aseptic processing, container-closure integrity, serialization, environmental monitoring, and end-to-end traceability. Hospitals and public purchasers increasingly weigh reliability, quality systems, and shortage resilience alongside price. Complex injectables, including products requiring specialized formulation, devices, or cold-chain handling, raise technical and regulatory barriers to entry. At the same time, procurement consolidation and essential-medicine policies are encouraging suppliers to demonstrate dependable capacity, diversified sourcing, and transparent risk management.

Artificial Intelligence Strengthens Quality, Planning, and Pharmacovigilance

Artificial intelligence can improve generic-injectable operations by supporting demand sensing, production scheduling, visual inspection, deviation triage, predictive maintenance, and inventory-risk monitoring. In development and regulatory work, machine learning can help organize formulation data, identify process signals, and prioritize documentation review. Adoption remains dependent on validated systems, representative data, cybersecurity, human oversight, and compliance with applicable good manufacturing and clinical practices. AI is therefore most useful as a controlled decision-support layer rather than a substitute for qualified personnel or established quality controls.

Regional Insights: Access Priorities Differ Across Six Geographies

North America emphasizes regulatory compliance, shortage prevention, hospital purchasing, and domestic or allied supply resilience. Latin America combines strong demand for affordable medicines with varied registration procedures, public-procurement structures, and logistics conditions. Europe places substantial weight on centralized or coordinated purchasing, pharmacovigilance, environmental performance, and manufacturing continuity. The Middle East is strengthening healthcare capacity while managing import dependence, localization objectives, and temperature-controlled distribution. Africa’s priorities include reliable essential-medicine access, quality-assurance capacity, and resilient last-mile logistics. Asia-Pacific spans advanced regulated markets and rapidly expanding healthcare systems, making local manufacturing capability, regulatory harmonization, and supply-chain diversification especially important.

Group Insights: Policy and Procurement Shape Market Access

ASEAN markets are influenced by regulatory variation, regional harmonization efforts, hospital demand, and the need to improve supply continuity across archipelagic and mainland distribution networks. BRICS economies combine large public-health requirements with differing regulatory systems, domestic-production policies, and procurement models. The European Union emphasizes common regulatory principles, coordinated health policy, and resilience across cross-border supply chains. G7 members generally apply demanding quality, safety, and pharmacovigilance standards while evaluating strategic dependence on external production. GCC countries are pursuing healthcare modernization, procurement coordination, and greater local or regional manufacturing capability. NATO members face shared concerns regarding critical-medicine resilience, continuity of care, and preparedness for disruptions.

Country Insights: Regulation, Production, and Access Priorities

Australia emphasizes national supply security, hospital procurement, and regulatory oversight across a geographically dispersed system. Brazil combines a large public health network with local-production and technology-transfer objectives. Canada focuses on shortage management, procurement reliability, and federal-provincial coordination. China is advancing domestic pharmaceutical capability while applying evolving regulatory and quality expectations. France and Germany operate within the European Union framework, with strong hospital demand and close attention to industrial resilience. India is a major manufacturing hub with extensive domestic demand and increasing emphasis on compliance and complex sterile production. Italy and Spain balance public procurement, budget discipline, and European supply-chain requirements. Japan prioritizes high-quality manufacturing, aging-population care, and supply continuity. Mexico is shaped by public procurement, regulatory modernization, and regional manufacturing links. Russia’s environment reflects domestic-supply priorities and constrained international access. South Korea combines advanced biopharmaceutical capabilities with rigorous regulation and export-oriented manufacturing. The United Kingdom emphasizes medicines resilience, centralized purchasing considerations, and post-EU regulatory coordination. The United States places strong emphasis on FDA compliance, shortage mitigation, hospital purchasing, and dependable sterile capacity.

Action Agenda for Leaders: Build Resilient, Compliant Injectable Operations

Industry leaders should prioritize validated aseptic capacity, robust contamination-control strategies, and continuous workforce qualification. They should diversify critical raw materials, active ingredients, components, and logistics routes while maintaining supplier-quality oversight and contingency inventories for clinically important products. Portfolio decisions should favor products where manufacturing complexity, clinical need, and supply reliability can be supported sustainably. Digital investments should begin with traceable use cases such as inspection, maintenance, planning, and deviation management, supported by data governance and validation. Leaders should also engage regulators, hospitals, group purchasers, and public-health agencies early to align packaging, labeling, shortage communication, and continuity plans with local requirements.

Research Methodology: Evidence-Led Assessment of Generic Injectables

This executive summary uses the defined market scope of generic injectables and synthesizes evidence-based themes across manufacturing, regulation, procurement, healthcare delivery, technology, and supply-chain resilience. The assessment is structured around required regional, multinational-group, and country geographies. It focuses on observable strategic drivers and operating conditions rather than numerical market estimates, shares, or forecasts. Interpretation should be supplemented with current regulatory publications, medicine-shortage notices, procurement documents, peer-reviewed literature, pharmacovigilance information, and company-specific quality disclosures when making investment or operational decisions.

Conclusion: Reliability and Quality Define Sustainable Advantage

Generic injectables remain strategically important because they support essential clinical treatment while helping healthcare systems manage affordability and access. Sustainable performance depends less on price alone than on sterile-manufacturing excellence, regulatory discipline, diversified supply, dependable procurement execution, and responsible use of digital tools. Organizations that combine high-quality operations with transparent resilience planning will be better positioned to support patients and healthcare providers across diverse markets.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Generic Injectables Market, by Drug Class
7.1. Introduction
7.2. Anti Infectives
7.2.1. Antibacterials
7.2.2. Antivirals
7.2.3. Antifungals
7.2.4. Antiparasitics
7.3. Cardiovascular Agents
7.3.1. Antihypertensives
7.3.2. Antiarrhythmics
7.3.3. Antithrombotic Agents
7.4. Central Nervous System Agents
7.4.1. Antiepileptics
7.4.2. Antipsychotics
7.4.3. Anxiolytics
7.5. Hormonal Agents
7.5.1. Insulins
7.5.2. Gonadal Hormones
7.6. Oncology Agents
7.6.1. Cytotoxic Agents
7.6.2. Targeted Therapies
7.6.3. Supportive Care Oncology Agents
7.7. Analgesics And Anesthetics
7.7.1. Opioid Analgesics
7.7.2. Non Opioid Analgesics
7.7.3. General Anesthetics
7.7.4. Local Anesthetics
7.8. Hematology Agents
7.8.1. Hemostatics
7.8.2. Hematinics
7.9. Immunomodulators
7.9.1. Immunosuppressants
7.9.2. Immunostimulants
7.10. Gastrointestinal Agents
7.10.1. Anti Ulcerants
7.10.2. Antiemetics
7.10.3. Prokinetics
8. Generic Injectables Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous
8.3. Intramuscular
8.4. Subcutaneous
8.5. Intradermal
8.6. Intrathecal
8.7. Intra Articular
8.8. Intra Peritoneal
9. Generic Injectables Market, by Container Type
9.1. Introduction
9.2. Vials
9.2.1. Single Dose Vials
9.2.2. Multi Dose Vials
9.3. Ampoules
9.4. Prefilled Syringes
9.5. Cartridges
9.6. Pens & Auto Injectors
10. Generic Injectables Market, by Therapeutic Area
10.1. Introduction
10.2. Oncology
10.2.1. Solid Tumors
10.2.2. Hematologic Malignancies
10.2.3. Supportive Care
10.3. Anti Infective
10.3.1. Antibacterial
10.3.2. Antiviral
10.3.3. Antifungal
10.3.4. Antiparasitic
10.4. Cardiovascular
10.4.1. Hypertension
10.4.2. Heart Failure
10.4.3. Arrhythmia
10.4.4. Antithrombotic Therapy
10.5. Central Nervous System
10.5.1. Anesthesia
10.5.2. Pain Management
10.5.3. Epilepsy
10.5.4. Psychiatric Disorders
10.6. Endocrinology And Metabolic
10.6.1. Diabetes
10.6.2. Thyroid Disorders
10.7. Gastrointestinal
10.7.1. Acid Related Disorders
10.7.2. Inflammatory Bowel Disease
10.8. Respiratory
10.8.1. Asthma
10.8.2. Chronic Obstructive Pulmonary Disease
10.9. Immunology
10.9.1. Autoimmune Disorders
10.9.2. Transplant Rejection Prophylaxis
10.10. Hematology Non Oncology
10.10.1. Anemia
10.10.2. Coagulation Disorders
11. Generic Injectables Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. Generic Injectables Market, by End User
12.1. Introduction
12.2. Hospitals
12.2.1. Public Hospitals
12.2.2. Private Hospitals
12.3. Ambulatory Surgical Centers
12.4. Clinics
12.5. Home Healthcare
12.6. Diagnostic And Imaging Centers
13. Generic Injectables Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Generic Injectables Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Generic Injectables Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Amgen Inc.
17.2. AstraZeneca PLC
17.3. Aurobindo Pharma Limited
17.4. Baxter International Inc.
17.5. Biocon Limited
17.6. Biological E. Limited
17.7. Bristol-Myers Squibb Company
17.8. Cipla Limited
17.9. Dr. Reddy's Laboratories Ltd.
17.10. Fresenius Kabi AG
17.11. Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd.
17.12. GlaxoSmithKline PLC
17.13. Hikma Pharmaceuticals PLC
17.14. Johnson & Johnson Services, Inc.
17.15. Lupin Limited
17.16. Mallinckrodt Pharmaceuticals plc
17.17. Meitheal Pharmaceuticals, Inc.
17.18. Merck & Co. Inc.
17.19. Novartis AG
17.20. Novo Nordisk A/S
17.21. Pfizer Inc.
17.22. Samsung Biologics Co., Ltd.
17.23. Sanofi S.A.
17.24. Somerset Pharma, LLC
17.25. Sun Pharmaceutical Industries Ltd.
17.26. Teva Pharmaceutical Industries Ltd.
17.27. Viatris Inc.
18. Key Experts
List of Figures
FIGURE 1. Global Generic Injectables Market, Years Considered for the Study
FIGURE 2. Global Generic Injectables Market, Research Design
FIGURE 3. Global Generic Injectables Market, Research Framework
FIGURE 4. Global Generic Injectables Market, Data Triangulation
FIGURE 5. Global Generic Injectables Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Generic Injectables Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Generic Injectables Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Generic Injectables Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Generic Injectables Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Generic Injectables Market Size, by Container Type, 2025 vs 2032 (%)
FIGURE 11. Global Generic Injectables Market Size, by Container Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Generic Injectables Market Size, by Therapeutic Area, 2025 vs 2032 (%)
FIGURE 13. Global Generic Injectables Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Generic Injectables Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Generic Injectables Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Generic Injectables Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Generic Injectables Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Generic Injectables Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Generic Injectables Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Generic Injectables Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Generic Injectables Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Generic Injectables Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Generic Injectables Market Share, by Key Player, 2025
List of Tables
TABLE 1. Global Generic Injectables Market Segmentation & Coverage
TABLE 2. Global Generic Injectables Market Size, 2017-2032 (USD Million)
TABLE 3. Global Generic Injectables Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Anti Infectives Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Anti Infectives Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Anti Infectives Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Antibacterials Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Antibacterials Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Antibacterials Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Antivirals Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Antivirals Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Antivirals Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Antifungals Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Antifungals Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Antifungals Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Antiparasitics Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Antiparasitics Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Antiparasitics Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Cardiovascular Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Cardiovascular Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Cardiovascular Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Antihypertensives Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Antihypertensives Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Antihypertensives Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Antiarrhythmics Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Antiarrhythmics Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Antiarrhythmics Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Antithrombotic Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Antithrombotic Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Antithrombotic Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Central Nervous System Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Central Nervous System Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Central Nervous System Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Antiepileptics Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Antiepileptics Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Antiepileptics Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Antipsychotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Antipsychotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Antipsychotics Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Anxiolytics Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Anxiolytics Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Anxiolytics Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Hormonal Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Hormonal Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Hormonal Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Insulins Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Insulins Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Insulins Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Gonadal Hormones Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Gonadal Hormones Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Gonadal Hormones Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Oncology Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Oncology Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Oncology Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Cytotoxic Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Cytotoxic Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Cytotoxic Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Targeted Therapies Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Targeted Therapies Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Targeted Therapies Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Supportive Care Oncology Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Supportive Care Oncology Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Supportive Care Oncology Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Analgesics And Anesthetics Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Analgesics And Anesthetics Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Analgesics And Anesthetics Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Opioid Analgesics Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Opioid Analgesics Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Opioid Analgesics Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Non Opioid Analgesics Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Non Opioid Analgesics Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Non Opioid Analgesics Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global General Anesthetics Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global General Anesthetics Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global General Anesthetics Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Local Anesthetics Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Local Anesthetics Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Local Anesthetics Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Hematology Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Hematology Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Hematology Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Hemostatics Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Hemostatics Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Hemostatics Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Hematinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Hematinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Hematinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Immunomodulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Immunomodulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Immunomodulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Immunosuppressants Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Immunosuppressants Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Immunosuppressants Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Immunostimulants Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Immunostimulants Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Immunostimulants Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Gastrointestinal Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Gastrointestinal Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Gastrointestinal Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Anti Ulcerants Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Anti Ulcerants Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Anti Ulcerants Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Antiemetics Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Antiemetics Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Antiemetics Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Prokinetics Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Prokinetics Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Prokinetics Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Generic Injectables Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 110. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 113. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 116. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 119. Global Intradermal Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Global Intradermal Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. Global Intradermal Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. Global Intrathecal Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Intrathecal Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Intrathecal Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global Intra Articular Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Intra Articular Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Intra Articular Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Intra Peritoneal Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global Intra Peritoneal Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global Intra Peritoneal Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global Generic Injectables Market Size, by Container Type, 2017-2032 (USD Million)
TABLE 132. Global Vials Market Size, by Region, 2017-2032 (USD Million)
TABLE 133. Global Vials Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. Global Vials Market Size, by Country, 2017-2032 (USD Million)
TABLE 135. Global Single Dose Vials Market Size, by Region, 2017-2032 (USD Million)
TABLE 136. Global Single Dose Vials Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. Global Single Dose Vials Market Size, by Country, 2017-2032 (USD Million)
TABLE 138. Global Multi Dose Vials Market Size, by Region, 2017-2032 (USD Million)
TABLE 139. Global Multi Dose Vials Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. Global Multi Dose Vials Market Size, by Country, 2017-2032 (USD Million)
TABLE 141. Global Ampoules Market Size, by Region, 2017-2032 (USD Million)
TABLE 142. Global Ampoules Market Size, by Group, 2017-2032 (USD Million)
TABLE 143. Global Ampoules Market Size, by Country, 2017-2032 (USD Million)
TABLE 144. Global Prefilled Syringes Market Size, by Region, 2017-2032 (USD Million)
TABLE 145. Global Prefilled Syringes Market Size, by Group, 2017-2032 (USD Million)
TABLE 146. Global Prefilled Syringes Market Size, by Country, 2017-2032 (USD Million)
TABLE 147. Global Cartridges Market Size, by Region, 2017-2032 (USD Million)
TABLE 148. Global Cartridges Market Size, by Group, 2017-2032 (USD Million)
TABLE 149. Global Cartridges Market Size, by Country, 2017-2032 (USD Million)
TABLE 150. Global Pens & Auto Injectors Market Size, by Region, 2017-2032 (USD Million)
TABLE 151. Global Pens & Auto Injectors Market Size, by Group, 2017-2032 (USD Million)
TABLE 152. Global Pens & Auto Injectors Market Size, by Country, 2017-2032 (USD Million)
TABLE 153. Global Generic Injectables Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 154. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 155. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 156. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 157. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 158. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 159. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 160. Global Hematologic Malignancies Market Size, by Region, 2017-2032 (USD Million)
TABLE 161. Global Hematologic Malignancies Market Size, by Group, 2017-2032 (USD Million)
TABLE 162. Global Hematologic Malignancies Market Size, by Country, 2017-2032 (USD Million)
TABLE 163. Global Supportive Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 164. Global Supportive Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 165. Global Supportive Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 166. Global Anti Infective Market Size, by Region, 2017-2032 (USD Million)
TABLE 167. Global Anti Infective Market Size, by Group, 2017-2032 (USD Million)
TABLE 168. Global Anti Infective Market Size, by Country, 2017-2032 (USD Million)
TABLE 169. Global Antibacterial Market Size, by Region, 2017-2032 (USD Million)
TABLE 170. Global Antibacterial Market Size, by Group, 2017-2032 (USD Million)
TABLE 171. Global Antibacterial Market Size, by Country, 2017-2032 (USD Million)
TABLE 172. Global Antiviral Market Size, by Region, 2017-2032 (USD Million)
TABLE 173. Global Antiviral Market Size, by Group, 2017-2032 (USD Million)
TABLE 174. Global Antiviral Market Size, by Country, 2017-2032 (USD Million)
TABLE 175. Global Antifungal Market Size, by Region, 2017-2032 (USD Million)
TABLE 176. Global Antifungal Market Size, by Group, 2017-2032 (USD Million)
TABLE 177. Global Antifungal Market Size, by Country, 2017-2032 (USD Million)
TABLE 178. Global Antiparasitic Market Size, by Region, 2017-2032 (USD Million)
TABLE 179. Global Antiparasitic Market Size, by Group, 2017-2032 (USD Million)
TABLE 180. Global Antiparasitic Market Size, by Country, 2017-2032 (USD Million)
TABLE 181. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
TABLE 182. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
TABLE 183. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
TABLE 184. Global Hypertension Market Size, by Region, 2017-2032 (USD Million)
TABLE 185. Global Hypertension Market Size, by Group, 2017-2032 (USD Million)
TABLE 186. Global Hypertension Market Size, by Country, 2017-2032 (USD Million)
TABLE 187. Global Heart Failure Market Size, by Region, 2017-2032 (USD Million)
TABLE 188. Global Heart Failure Market Size, by Group, 2017-2032 (USD Million)
TABLE 189. Global Heart Failure Market Size, by Country, 2017-2032 (USD Million)
TABLE 190. Global Arrhythmia Market Size, by Region, 2017-2032 (USD Million)
TABLE 191. Global Arrhythmia Market Size, by Group, 2017-2032 (USD Million)
TABLE 192. Global Arrhythmia Market Size, by Country, 2017-2032 (USD Million)
TABLE 193. Global Antithrombotic Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 194. Global Antithrombotic Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 195. Global Antithrombotic Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 196. Global Central Nervous System Market Size, by Region, 2017-2032 (USD Million)
TABLE 197. Global Central Nervous System Market Size, by Group, 2017-2032 (USD Million)
TABLE 198. Global Central Nervous System Market Size, by Country, 2017-2032 (USD Million)
TABLE 199. Global Anesthesia Market Size, by Region, 2017-2032 (USD Million)
TABLE 200. Global Anesthesia Market Size, by Group, 2017-2032 (USD Million)
TABLE 201. Global Anesthesia Market Size, by Country, 2017-2032 (USD Million)
TABLE 202. Global Pain Management Market Size, by Region, 2017-2032 (USD Million)
TABLE 203. Global Pain Management Market Size, by Group, 2017-2032 (USD Million)
TABLE 204. Global Pain Management Market Size, by Country, 2017-2032 (USD Million)
TABLE 205. Global Epilepsy Market Size, by Region, 2017-2032 (USD Million)
TABLE 206. Global Epilepsy Market Size, by Group, 2017-2032 (USD Million)
TABLE 207. Global Epilepsy Market Size, by Country, 2017-2032 (USD Million)
TABLE 208. Global Psychiatric Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 209. Global Psychiatric Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 210. Global Psychiatric Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 211. Global Endocrinology And Metabolic Market Size, by Region, 2017-2032 (USD Million)
TABLE 212. Global Endocrinology And Metabolic Market Size, by Group, 2017-2032 (USD Million)
TABLE 213. Global Endocrinology And Metabolic Market Size, by Country, 2017-2032 (USD Million)
TABLE 214. Global Diabetes Market Size, by Region, 2017-2032 (USD Million)
TABLE 215. Global Diabetes Market Size, by Group, 2017-2032 (USD Million)
TABLE 216. Global Diabetes Market Size, by Country, 2017-2032 (USD Million)
TABLE 217. Global Thyroid Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 218. Global Thyroid Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 219. Global Thyroid Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 220. Global Gastrointestinal Market Size, by Region, 2017-2032 (USD Million)
TABLE 221. Global Gastrointestinal Market Size, by Group, 2017-2032 (USD Million)
TABLE 222. Global Gastrointestinal Market Size, by Country, 2017-2032 (USD Million)
TABLE 223. Global Acid Related Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 224. Global Acid Related Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 225. Global Acid Related Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 226. Global Inflammatory Bowel Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 227. Global Inflammatory Bowel Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 228. Global Inflammatory Bowel Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 229. Global Respiratory Market Size, by Region, 2017-2032 (USD Million)
TABLE 230. Global Respiratory Market Size, by Group, 2017-2032 (USD Million)
TABLE 231. Global Respiratory Market Size, by Country, 2017-2032 (USD Million)
TABLE 232. Global Asthma Market Size, by Region, 2017-2032 (USD Million)
TABLE 233. Global Asthma Market Size, by Group, 2017-2032 (USD Million)
TABLE 234. Global Asthma Market Size, by Country, 2017-2032 (USD Million)
TABLE 235. Global Chronic Obstructive Pulmonary Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 236. Global Chronic Obstructive Pulmonary Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 237. Global Chronic Obstructive Pulmonary Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 238. Global Immunology Market Size, by Region, 2017-2032 (USD Million)
TABLE 239. Global Immunology Market Size, by Group, 2017-2032 (USD Million)
TABLE 240. Global Immunology Market Size, by Country, 2017-2032 (USD Million)
TABLE 241. Global Autoimmune Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 242. Global Autoimmune Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 243. Global Autoimmune Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 244. Global Transplant Rejection Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 245. Global Transplant Rejection Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 246. Global Transplant Rejection Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
TABLE 247. Global Hematology Non Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 248. Global Hematology Non Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 249. Global Hematology Non Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 250. Global Anemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 251. Global Anemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 252. Global Anemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 253. Global Coagulation Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 254. Global Coagulation Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 255. Global Coagulation Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 256. Global Generic Injectables Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 257. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 258. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 259. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 260. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 261. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 262. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 263. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 264. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 265. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 266. Global Generic Injectables Market Size, by End User, 2017-2032 (USD Million)
TABLE 267. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 268. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 269. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 270. Global Public Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 271. Global Public Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 272. Global Public Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 273. Global Private Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 274. Global Private Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 275. Global Private Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 276. Global Ambulatory Surgical Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 277. Global Ambulatory Surgical Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 278. Global Ambulatory Surgical Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 279. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 280. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 281. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 282. Global Home Healthcare Market Size, by Region, 2017-2032 (USD Million)
TABLE 283. Global Home Healthcare Market Size, by Group, 2017-2032 (USD Million)
TABLE 284. Global Home Healthcare Market Size, by Country, 2017-2032 (USD Million)
TABLE 285. Global Diagnostic And Imaging Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 286. Global Diagnostic And Imaging Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 287. Global Diagnostic And Imaging Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 288. Global Generic Injectables Market Size, by Region, 2017-2032 (USD Million)
TABLE 289. Asia-Pacific Generic Injectables Market Size, by Region, 2017-2032 (USD Million)
TABLE 290. Asia-Pacific Generic Injectables Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 291. Asia-Pacific Generic Injectables Market Size, by Anti Infectives, 2017-2032 (USD Million)
TABLE 292. Asia-Pacific Generic Injectables Market Size, by Cardiovascular Agents, 2017-2032 (USD Million)
TABLE 293. Asia-Pacific Generic Injectables Market Size, by Central Nervous System Agents, 2017-2032 (USD Million)
TABLE 294. Asia-Pacific Generic Injectables Market Size, by Hormonal Agents, 2017-2032 (USD Million)
TABLE 295. Asia-Pacific Generic Injectables Market Size, by Oncology Agents, 2017-2032 (USD Million)
TABLE 296. Asia-Pacific Generic Injectables Market Size, by Analgesics And Anesthetics, 2017-2032 (USD Million)
TABLE 297. Asia-Pacific Generic Injectables Market Size, by Hematology Agents, 2017-2032 (USD Million)
TABLE 298. Asia-Pacific Generic Injectables Market Size, by Immunomodulators, 2017-2032 (USD Million)
TABLE 299. Asia-Pacific Generic Injectables Market Size, by Gastrointestinal Agents, 2017-2032 (USD Million)
TABLE 300. Asia-Pacific Generic Injectables Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 301. Asia-Pacific Generic Injectables Market Size, by Container Type, 2017-2032 (USD Million)
TABLE 302. Asia-Pacific Generic Injectables Market Size, by Vials, 2017-2032 (USD Million)
TABLE 303. Asia-Pacific Generic Injectables Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 304. Asia-Pacific Generic Injectables Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 305. Asia-Pacific Generic Injectables Market Size, by Anti Infective, 2017-2032 (USD Million)
TABLE 306. Asia-Pacific Generic Injectables Market Size, by Cardiovascular, 2017-2032 (USD Million)
TABLE 307. Asia-Pacific Generic Injectables Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 308. Asia-Pacific Generic Injectables Market Size, by Endocrinology And Metabolic, 2017-2032 (USD Million)
TABLE 309. Asia-Pacific Generic Injectables Market Size, by Gastrointestinal, 2017-2032 (USD Million)
TABLE 310. Asia-Pacific Generic Injectables Market Size, by Respiratory, 2017-2032 (USD Million)
TABLE 311. Asia-Pacific Generic Injectables Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 312. Asia-Pacific Generic Injectables Market Size, by Hematology Non Oncology, 2017-2032 (USD Million)
TABLE 313. Asia-Pacific Generic Injectables Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 314. Asia-Pacific Generic Injectables Market Size, by End User, 2017-2032 (USD Million)
TABLE 315. Asia-Pacific Generic Injectables Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 316. North America Generic Injectables Market Size, by Region, 2017-2032 (USD Million)
TABLE 317. North America Generic Injectables Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 318. North America Generic Injectables Market Size, by Anti Infectives, 2017-2032 (USD Million)
TABLE 319. North America Generic Injectables Market Size, by Cardiovascular Agents, 2017-2032 (USD Million)
TABLE 320. North America Generic Injectables Market Size, by Central Nervous System Agents, 2017-2032 (USD Million)
TABLE 321. North America Generic Injectables Market Size, by Hormonal Agents, 2017-2032 (USD Million)
TABLE 322. North America Generic Injectables Market Size, by Oncology Agents, 2017-2032 (USD Million)
TABLE 323. North America Generic Injectables Market Size, by Analgesics And Anesthetics, 2017-2032 (USD Million)
TABLE 324. North America Generic Injectables Market Size, by Hematology Agents, 2017-2032 (USD Million)
TABLE 325. North America Generic Injectables Market Size, by Immunomodulators, 2017-2032 (USD Million)
TABLE 326. North America Generic Injectables Market Size, by Gastrointestinal Agents, 2017-2032 (USD Million)
TABLE 327. North America Generic Injectables Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 328. North America Generic Injectables Market Size, by Container Type, 2017-2032 (USD Million)
TABLE 329. North America Generic Injectables Market Size, by Vials, 2017-2032 (USD Million)
TABLE 330. North America Generic Injectables Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 331. North America Generic Injectables Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 332. North America Generic Injectables Market Size, by Anti Infective, 2017-2032 (USD Million)
TABLE 333. North America Generic Injectables Market Size, by Cardiovascular, 2017-2032 (USD Million)
TABLE 334. North America Generic Injectables Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 335. North America Generic Injectables Market Size, by Endocrinology And Metabolic, 2017-2032 (USD Million)
TABLE 336. North America Generic Injectables Market Size, by Gastrointestinal, 2017-2032 (USD Million)
TABLE 337. North America Generic Injectables Market Size, by Respiratory, 2017-2032 (USD Million)
TABLE 338. North America Generic Injectables Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 339. North America Generic Injectables Market Size, by Hematology Non Oncology, 2017-2032 (USD Million)
TABLE 340. North America Generic Injectables Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 341. North America Generic Injectables Market Size, by End User, 2017-2032 (USD Million)
TABLE 342. North America Generic Injectables Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 343. Latin America Generic Injectables Market Size, by Region, 2017-2032 (USD Million)
TABLE 344. Latin America Generic Injectables Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 345. Latin America Generic Injectables Market Size, by Anti Infectives, 2017-2032 (USD Million)
TABLE 346. Latin America Generic Injectables Market Size, by Cardiovascular Agents, 2017-2032 (USD Million)
TABLE 347. Latin America Generic Injectables Market Size, by Central Nervous System Agents, 2017-2032 (USD Million)
TABLE 348. Latin America Generic Injectables Market Size, by Hormonal Agents, 2017-2032 (USD Million)
TABLE 349. Latin America Generic Injectables Market Size, by Oncology Agents, 2017-2032 (USD Million)
TABLE 350. Latin America Generic Injectables Market Size, by Analgesics And Anesthetics, 2017-2032 (USD Million)
TABLE 351. Latin America Generic Injectables Market Size, by Hematology Agents, 2017-2032 (USD Million)
TABLE 352. Latin America Generic Injectables Market Size, by Immunomodulators, 2017-2032 (USD Million)
TABLE 353. Latin America Generic Injectables Market Size, by Gastrointestinal Agents, 2017-2032 (USD Million)
TABLE 354. Latin America Generic Injectables Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 355. Latin America Generic Injectables Market Size, by Container Type, 2017-2032 (USD Million)
TABLE 356. Latin America Generic Injectables Market Size, by Vials, 2017-2032 (USD Million)
TABLE 357. Latin America Generic Injectables Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 358. Latin America Generic Injectables Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 359. Latin America Generic Injectables Market Size, by Anti Infective, 2017-2032 (USD Million)
TABLE 360. Latin America Generic Injectables Market Size, by Cardiovascular, 2017-2032 (USD Million)
TABLE 361. Latin America Generic Injectables Market Size, by Central Nervous System, 2017-2032 (USD Million)
TABLE 362. Latin America Generic Injectables Market Size, by Endocrinology And Metabolic, 2017-2032 (USD Million)
TABLE 363. Latin America Generic Injectables Market Size, by Gastrointestinal, 2017-2032 (USD Million)
TABLE 364. Latin America Generic Injectables Market Size, by Respiratory, 2017-2032 (USD Million)
TABLE 365. Latin America Generic Injectables Market Size, by Immunology, 2017-2032 (USD Million)
TABLE 366. Latin America Generic Injectables Market Size, by Hematology Non Oncology, 2017-2032 (USD Million)
TABLE 367. Latin America Generic Injectables Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 368. Latin America Generic Injectables Market Size, by End User, 2017-2032 (USD Million)
TABLE 369. Latin America Generic Injectables Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 370. Europe Generic Injectables Market Size, by Region, 2017-2032 (USD Million)
TABLE 371. Europe Generic Injectables Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 372. Europe Generic Injectables Market Size, by Anti Infectives, 2017-2032 (USD Million)
TABLE 373. Europe Generic Injectables Market Size, by Cardiovascular Agents, 2017-2032 (USD Million)
TABLE 374. Europe Generic Injectables Market Size, by Central Nervous System Agents, 2017-2032 (USD Million)
TABLE 375. Europe Generic Injectables Market Size, by Hormonal Agents, 2017-2032 (USD Million)
TABLE 376. Europe Generic Injectables Market Size, by

Companies Mentioned

  • Amgen Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Biocon Limited
  • Biological E. Limited
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Mallinckrodt Pharmaceuticals plc
  • Meitheal Pharmaceuticals, Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Samsung Biologics Co., Ltd.
  • Sanofi S.A.
  • Somerset Pharma, LLC
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 44.05 Billion
Forecasted Market Value ( USD ) by 2032 $ 84.1 Billion
Compound Annual Growth Rate11.1%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Injectable Drugs Market - Global Forecast 2026-2032 - Product Image

Injectable Drugs Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Sustained Release Injectables Market - Global Forecast 2026-2032 - Product Image

Sustained Release Injectables Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Sterile Injectable Drugs - Global Strategic Business Report - Product Image

Sterile Injectable Drugs - Global Strategic Business Report

  • Report
  • 345 Pages
  • Global
From
Injectable Cytotoxic Drugs - Global Strategic Business Report - Product Image

Injectable Cytotoxic Drugs - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Generic Injectables Market Report by Therapeutic Area, Container, Distribution Channel, and Region 2026-2034 - Product Image

Generic Injectables Market Report by Therapeutic Area, Container, Distribution Channel, and Region 2026-2034

  • Report
  • 140 Pages
  • Global
From

About the Generic Injectable Market

The Generic Injectable market is a segment of the drug delivery industry that focuses on the production and distribution of generic injectable drugs. These drugs are typically administered via injection and are used to treat a variety of medical conditions. Generic injectables are typically cheaper than their branded counterparts, making them a popular choice for patients and healthcare providers alike. Generic injectables are typically produced in bulk and then packaged and distributed to pharmacies and hospitals. The production process involves the use of sterile manufacturing techniques and quality control measures to ensure the safety and efficacy of the drugs. Generic injectables are an important part of the drug delivery industry, as they provide an affordable and effective way to treat a variety of medical conditions. Some companies in the Generic Injectable market include Hospira, Mylan, Teva Pharmaceuticals, Sandoz, and Fresenius Kabi. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.